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Background
Varenicline is currently the most effective smoking cessa-
tion medication. Pre-marketing clinical trials excluded
participants with psychiatric disorders, such as major
depressive disorders. This study investigated the psychia-
tric effects of varenicline among patients with depression.
Methods
On 18 December 2012, a systematic search was per-
formed using Medline with the following search terms:
1) varenicline and 2) depression. The search was limited
to English articles, case reports, and original clinical stu-
dies. From the 58 retrieved documents, 15 articles were
used in this review.
Results
The first case report on the effects of varenicline on
patients with depression was published in June 2008. A
man experienced an acute exacerbation of depressive
symptoms, which resolved after he stopped his varenicline
treatment. [1] Since then, there were 8 other case reports
that described exacerbation of psychiatric symptoms in
patients with depression taking varenicline [2-9]. Two of
those case studies suggested the use of sertraline [7] and
bupropion [8] to treat exacerbation of depressive symp-
toms associated with varenicline. In contrast, varenicline
was shown to improve the affective symptoms of a smoker
who developed depression and suicidal tendencies during
previous cessation attempts [10]. There were 3 observa-
tional studies on patients with depression taking vareni-
cline: 1) a one-year follow-up study on 112 smokers
showed an association between increased Beck Depression
Inventory score and continued smoking after 12 weeks of
varenicline [11]; 2) an open-labelled study showed signifi-
cant improvement in mood in 110 outpatient smokers
with persistent depressive symptoms [12]; and 3) A smok-
ing cessation trial on 217 varenicline users showed that
depressive symptoms at the time of varenicline initiation
(measured by Patient Health Questionnaire-2) were asso-
ciated with suicidal ideation. [13] There were 2 clinical
trials on patients with depression taking varenicline, with
both of them showing worsening of psychiatric symptoms.
[14,15] Neither of the trials were placebo-controlled.
Conclusions
Despite some inconsistencies, the findings suggested
that varenicline could worsen psychiatric symptoms in
patients with depression. Clinicians should be advised to
closely monitor patients with a history of depression on
varenicline, although there were no studies on how to
treat those patients. Bias and uncontrolled confounders
potentially affected previous studies, and thus, a double-
blinded placebo-controlled trial is needed to demon-
strate the efficacy and side effects of varenicline on
patients with depression.
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